Pfizer fails to end lawsuit over Bextra, Celebrex safety
March 28 (Reuters) - Pfizer Inc has failed to persuade a federal judge to dismiss a shareholder lawsuit accusing the company of fraudulently misrepresenting the cardiovascular risks associated with its Bextra and Celebrex pain-relieving drugs.
While dismissing some of the shareholders' claims, U.S. District Judge Laura Taylor Swain in Manhattan said it was premature to dismiss the entire case.
Swain said a reasonable jury could find that Pfizer intended to mislead shareholders through its disclosures about the drugs' safety.
The plaintiffs are led by the Teachers' Retirement System of Louisiana, and a class was certified on July 5, 2012.
- Protesters fell Lenin statue, tell Ukraine's president 'you're next'
- Four dead in apparent Connecticut murder-suicide
- South Korea expands air defense zone to partially overlap China's |
- Singer Susan Boyle reveals she has Asperger's syndrome: paper
- Dynasty's Congress party punished in Indian state elections